PPD™ Laboratory Services

WRIB 2026 is fast approaching! Engage with our experts and explore new partnership possibilities by visiting us at booth 24, April 13-17 in Dallas, Texas. Learn more » http://spr.ly/6041B6X7tJ

Our bioanalytical laboratories have extensive experience in bioanalysis across a vast spectrum of drug development projects and can help develop effective solutions, from simple to the most complex analytical challenges. Learn more about our new bioanalytical lab in Sweden: http://spr.ly/6047B6X7kl

Mycoplasma testing is conducted to ensure biopharmaceutical products are free of contaminants, helping deliver safe medicines for patients. Existing testing can be lengthy and complex, so our GMP lab has developed novel protocols suitable for testing a variety of samples. Learn how our new testing protocols can benefit biologics companies and help accelerate the manufacturing process for cell and gene therapies. ⬇️

Our PERT assay is the newest offering in our comprehensive suite of biosafety testing services. This validated, GMP- and USP-compliant method is for the rapid and reliable detection of RT activity associated with retroviruses. The one-step RT-PCR format reduces contamination risk and provides high-confidence results with a two-day TAT, helping accelerate safe and compliant development of new therapies. Learn more » http://spr.ly/6042h4gto

We offer an extensive range of advanced testing services, depth of knowledge in many therapeutic areas, and the scientific acumen needed to advance successful drug programs at every stage of the drug development process. Learn more » http://spr.ly/6040h4ggs

We are excited to attend #DCATWeek 2026, where we’ll showcase our GMP lab services and Accelerator™ Drug Development, 360° #CDMO and #CRO solutions. We help sponsors and customers of all sizes navigate every milestone of the drug development journey with a unified, one-team approach. To learn more about our capabilities, connect with our industry experts at DCAT Week 2026. You can book a meeting with us here: http://spr.ly/6047h2YPZ

We’re pleased to share our new white paper about approaches in creating a mycoplasma-free environment. In the white paper, our experts cover how using the MycoSEQ™ Plus protocol, especially for CGTs, can help determine contamination causes and establish alert and action levels for mycoplasma, enabling prompt actions to ensure the safety of manufacturing processes. 📥 » http://spr.ly/6048hvgEK

Attending WRIB 2026 on April 13-17 in Dallas, Texas? Engage with our experts and explore new partnership possibilities by visiting us at booth 24. Learn more: http://spr.ly/6047hZ2HU

Our biomarker team has extensive experience in biomarker solutions across a vast spectrum of drug development projects and can help develop effective solutions from simple to the most complex analytical challenges. Learn more about our comprehensive biomarker solutions. » http://spr.ly/6044hZFAp

Testing for mycoplasma contamination is critical because several species are pathogenic. Traditional culture methods remain the gold standard for mycoplasma detection, but they are slow and time-consuming, which poses challenges for products with short shelf lives such as cell and gene therapy (CGT) products. Our blog highlights how molecular testing can provide sensitive and specific results more rapidly. ⬇️